The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance.
The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance.
About this item
Full title
Author / Creator
Pei, Jun and Han, Baohui
Publisher
China: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Journal title
Language
Chinese
Formats
Publication information
Publisher
China: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Subjects
More information
Scope and Contents
Contents
肺癌是目前世界范围内发病率和死亡率最高的恶性肿瘤，表皮生长因子受体（epidermal growth factor receptor, EGFR）基因在肺癌的发生发展过程中起了重要作用。以EGFR为靶点的分子靶向药物的出现为肺癌的治疗带来了新的希望。以吉非替尼（ZD1839，易瑞沙）和厄洛替尼（OSI-774，特罗凯）为代表的酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）是目前被多国批准并广泛应用于进展或难治性非小细胞肺癌（non-small cell lung cancer, NSCLC）的小分子靶向药物。最初的临床实践发现化疗失败的非小细胞肺癌病人对TKI药物治疗的总有效率可达10%以上。进一步的亚组分析发现[1-3]，东方人、腺癌、女性和不吸烟者是TK...
Alternative Titles
Full title
The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance.
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_82f5e929586241ff96125efa22697435
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_82f5e929586241ff96125efa22697435
Other Identifiers
ISSN
1009-3419
E-ISSN
1999-6187
DOI
10.3779/j.issn.1009-3419.2009.12.21
